A small study found that boys with Duchenne muscular dystrophy who took the drug ACE-031 maintained their walking distance better than those on placebo, but the difference was not statistically significant.
See the scientific wording
In a small randomized controlled trial, treatment with the myostatin inhibitor ACE-031 in ambulatory boys with Duchenne muscular dystrophy showed a trend for maintenance of 6-minute walk test distance over the study period compared to a decline in the placebo group, though the difference was not statistically significant.
Strong evidence
Randomized trialsOne moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2017
The study found that boys who got the drug walked about the same distance over time, while those on placebo walked less, but the difference could have been due to chance.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
ACE-031 is a drug that blocks myostatin, a natural protein that tells muscles to stop growing. In boys with Duchenne muscular dystrophy, muscles are weak and break down. By blocking myostatin, ACE-031 removes this brake, allowing muscles to grow stronger and stay bigger. This helps boys walk farther over time, though the effect is small.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
A small study found that boys with Duchenne muscular dystrophy who took the drug ACE-031 maintained their walking distance better than those on placebo, but the difference was not statistically significant.
Mechanism
1 studyACE-031 works by blocking a natural protein called myostatin that stops muscle growth. In Duchenne muscular dystrophy, muscles waste away, but blocking myostatin helps muscles grow and stay stronger. This helps boys with the disease walk about the same distance over time instead of losing ground. The effect is supported by increases in muscle mass, but the improvement in walking distance was small and not conclusive.
ACE-031 is a drug that blocks myostatin, a natural protein that tells muscles to stop growing. In boys with Duchenne muscular dystrophy, muscles are weak and break down. By blocking myostatin, ACE-031 removes this brake, allowing muscles to grow stronger and stay bigger. This helps boys walk farther over time, though the effect is small.
ACE-031 binds to myostatin and related ligands (activin A, GDF-11) in the circulation, preventing them from interacting with native activin receptor type IIB on muscle cells.
Blockade of activin receptor type IIB reduces Smad2/3 phosphorylation, which normally suppresses muscle gene expression and protein synthesis.
Removal of Smad-mediated suppression increases muscle protein synthesis and myogenesis, leading to gain in lean body mass and maintenance of muscle function.
Improved muscle mass and function counteract the natural decline in ambulatory ability in Duchenne muscular dystrophy, resulting in stabilization of 6-minute walk test distance.
Evidence from Studies
Supporting (1)
Community contributions welcome
Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial
The study found that boys who got the drug walked about the same distance over time, while those on placebo walked less, but the difference could have been due to chance.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Myostatin Inhibitors for Duchenne Muscular Dystrophy
Comprehensive search of databases for RCTs of myostatin inhibitors (including ACE-031) in ambulatory boys with DMD, with meta-analysis of primary outcomes (6-minute walk distance change) and secondary outcomes, using appropriate quality assessment and subgroup analyses.
Confirmatory Phase 3 RCT of ACE-031 in Duchenne Muscular Dystrophy
Double-blind, placebo-controlled, parallel-group RCT enrolling at least 100 ambulatory boys with DMD (ages 5-15), randomized 1:1 to ACE-031 (dose determined from phase 2) or placebo for 48 weeks, with primary endpoint change in 6-minute walk distance from baseline to week 48. Secondary outcomes: timed function tests, muscle strength, adverse events.
Long-term Cohort Study of ACE-031 Treatment in DMD
Prospective cohort of ambulatory boys with DMD initiating ACE-031 treatment (based on clinical availability) matched to a control cohort receiving standard care, followed for 2-5 years with regular assessments of 6-minute walk distance, pulmonary function, and survival. Covariates: age, steroid use, baseline function.
In Vitro Study of ACE-031 on Myoblast Differentiation in DMD Cell Lines
Culture of myoblasts derived from DMD patient biopsies, treated with ACE-031 at varying concentrations, measurement of myotube diameter, fusion index, and expression of myogenic markers (MyoD, myogenin) and dystrophin-associated proteins. Comparison to healthy control myoblasts.
ACE-031 Treatment in mdx Mice: Effects on Muscle Function and Histology
Randomized controlled animal study: mdx mice (dystrophin-deficient) treated with ACE-031 (subcutaneous injections) vs. vehicle for 12 weeks, with assessments of grip strength, treadmill running time, and post-mortem muscle histology (fiber size, necrosis, fibrosis).